Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 28 August 1998:
Vol. 281. no. 5381, pp. 1349 - 1352
DOI: 10.1126/science.281.5381.1349
Prev | Table of Contents | Next

Reports

Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats

Bita Moghaddam, * Barbara W. Adams

Glutamatergic abnormalities have been associated with several psychiatric disorders, including schizophrenia and addiction. Group II metabotropic glutamate receptors were targeted to normalize glutamatergic disruptions associated with an animal model of schizophrenia, the phencyclidine model. An agonist of this group of receptors, at a dose that was without effects on spontaneous activity and corticolimbic dopamine neurotransmission, attenuated the disruptive effects of phencyclidine on working memory, stereotypy, locomotion, and cortical glutamate efflux. This behavioral reversal occurred in spite of sustained dopamine hyperactivity. Thus, targeting this group of receptors may present a nondopaminergic therapeutic strategy for treatment of psychiatric disorders.

Department of Psychiatry, Yale University School of Medicine, Veterans Administration Medical Center 116A/2, West Haven, CT 06516, USA.
*   To whom correspondence should be addressed. E-mail: bita.moghaddam{at}yale.edu

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
How High-Resolution Basal-State Functional Imaging Can Guide the Development of New Pharmacotherapies for Schizophrenia.
I. Gaisler-Salomon, S. A. Schobel, S. A. Small, and S. Rayport (2009)
Schizophr Bull 35, 1037-1044
   Abstract »    Full Text »    PDF »
Neuroactive Steroid Dehydroepiandrosterone Sulfate Inhibits 5-Hydroxytryptamine (5-HT)-Evoked Glutamate Release via Activation of {sigma}-1 Receptors and Then Inhibition of 5-HT3 Receptors in Rat Prelimbic Cortex.
L. Dong, Y. Zhu, Y. Dong, J. Yang, Y. Zhao, Y. Qi, P. Wu, Y. Zhu, and P. Zheng (2009)
J. Pharmacol. Exp. Ther. 330, 494-501
   Abstract »    Full Text »    PDF »
Validating Novel Targets for Pharmacological Interventions in Schizophrenia.
B. Wroblewska and D. A. Lewis (2009)
Am J Psychiatry 166, 753-756
   Full Text »    PDF »
Differential Expression of Metabotropic Glutamate Receptors 2 and 3 in Schizophrenia: A Mechanism for Antipsychotic Drug Action?.
S. Ghose, K. A. Gleason, B. W. Potts, K. Lewis-Amezcua, and C. A. Tamminga (2009)
Am J Psychiatry 166, 812-820
   Abstract »    Full Text »    PDF »
Unique Antipsychotic Activities of the Selective Metabotropic Glutamate Receptor 1 Allosteric Antagonist 2-Cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one.
A. Satow, G. Suzuki, S. Maehara, H. Hikichi, T. Murai, T. Murai, H. Kawagoe-Takaki, M. Hata, S. Ito, S. Ozaki, et al. (2009)
J. Pharmacol. Exp. Ther. 330, 179-190
   Abstract »    Full Text »    PDF »
Neuroimaging and Physiological Evidence for Involvement of Glutamatergic Transmission in Regulation of the Striatal Dopaminergic System.
M. Tokunaga, N. Seneca, R.-M. Shin, J. Maeda, S. Obayashi, T. Okauchi, Y. Nagai, M.-R. Zhang, R. Nakao, H. Ito, et al. (2009)
J. Neurosci. 29, 1887-1896
   Abstract »    Full Text »    PDF »
Transepithelial Transport of the Group II Metabotropic Glutamate 2/3 Receptor Agonist (1S,2S,5R,6S)-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) and Its Prodrug (1S,2S,5R,6S)-2-[(2'S)-(2'-Amino)propionyl]aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY544344).
M. V. S. Varma, A. H. Eriksson, G. Sawada, Y. A. Pak, E. J. Perkins, and C. L. Zimmerman (2009)
Drug Metab. Dispos. 37, 211-220
   Abstract »    Full Text »    PDF »
Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection.
J. A. Lieberman, F. P. Bymaster, H. Y. Meltzer, A. Y. Deutch, G. E. Duncan, C. E. Marx, J. R. Aprille, D. S. Dwyer, X.-M. Li, S. P. Mahadik, et al. (2008)
Pharmacol. Rev. 60, 358-403
   Abstract »    Full Text »    PDF »
Pharmacological Effects of the Metabotropic Glutamate Receptor 1 Antagonist Compared with Those of the Metabotropic Glutamate Receptor 5 Antagonist and Metabotropic Glutamate Receptor 2/3 Agonist in Rodents: Detailed Investigations with a Selective Allosteric Metabotropic Glutamate Receptor 1 Antagonist, FTIDC [4-[1-(2-Fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide].
A. Satow, S. Maehara, S. Ise, H. Hikichi, M. Fukushima, G. Suzuki, T. Kimura, T. Tanaka, S. Ito, H. Kawamoto, et al. (2008)
J. Pharmacol. Exp. Ther. 326, 577-586
   Abstract »    Full Text »    PDF »
Evidence for the Role of Metabotropic Glutamate (mGlu)2 Not mGlu3 Receptors in the Preclinical Antipsychotic Pharmacology of the mGlu2/3 Receptor Agonist (-)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic Acid (LY404039).
M. J. Fell, K. A. Svensson, B. G. Johnson, and D. D. Schoepp (2008)
J. Pharmacol. Exp. Ther. 326, 209-217
   Abstract »    Full Text »    PDF »
Review: The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia.
P. Harrison, L. Lyon, L. Sartorius, P. Burnet, and T. Lane (2008)
J Psychopharmacol 22, 308-322
   Abstract »    PDF »
Schizophrenia: Moving Beyond Monoamine Antagonists.
P. J. Conn, C. Tamminga, D. D. Schoepp, and C. Lindsley (2008)
Mol. Interv. 8, 99-107
   Abstract »    Full Text »    PDF »
Glutamate and the Neural Basis of the Subjective Effects of Ketamine: A Pharmaco-Magnetic Resonance Imaging Study.
J. F. W. Deakin, J. Lees, S. McKie, J. E. C. Hallak, S. R. Williams, and S. M. Dursun (2008)
Arch Gen Psychiatry 65, 154-164
   Abstract »    Full Text »    PDF »
NMDA Receptor Hypofunction Produces Opposite Effects on Prefrontal Cortex Interneurons and Pyramidal Neurons.
H. Homayoun and B. Moghaddam (2007)
J. Neurosci. 27, 11496-11500
   Abstract »    Full Text »    PDF »
Recent Advances in the Development of Novel Pharmacological Agents for the Treatment of Cognitive Impairments in Schizophrenia.
R. W. Buchanan, R. Freedman, D. C. Javitt, A. Abi-Dargham, and J. A. Lieberman (2007)
Schizophr Bull 33, 1120-1130
   Abstract »    Full Text »    PDF »
Dysfunctional and Compensatory Prefrontal Cortical Systems, Genes and the Pathogenesis of Schizophrenia.
H.-Y. Tan, J. H. Callicott, and D. R. Weinberger (2007)
Cereb Cortex 17, i171-i181
   Abstract »    Full Text »    PDF »
A Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 2 Blocks a Hallucinogenic Drug Model of Psychosis.
M. A. Benneyworth, Z. Xiang, R. L. Smith, E. E. Garcia, P. J. Conn, and E. Sanders-Bush (2007)
Mol. Pharmacol. 72, 477-484
   Abstract »    Full Text »    PDF »
Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function.
H.-Y. Tan, Q. Chen, S. Sust, J. W. Buckholtz, J. D. Meyers, M. F. Egan, V. S. Mattay, A. Meyer-Lindenberg, D. R. Weinberger, and J. H. Callicott (2007)
PNAS 104, 12536-12541
   Abstract »    Full Text »    PDF »
Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?.
C. H. Large (2007)
J Psychopharmacol 21, 283-301
   Abstract »    PDF »
Pharmacological and Pharmacokinetic Properties of a Structurally Novel, Potent, and Selective Metabotropic Glutamate 2/3 Receptor Agonist: In Vitro Characterization of Agonist (-)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic Acid (LY404039).
L. M. Rorick-Kehn, B. G. Johnson, J. L. Burkey, R. A. Wright, D. O. Calligaro, G. J. Marek, E. S. Nisenbaum, J. T. Catlow, A. E. Kingston, D. D. Giera, et al. (2007)
J. Pharmacol. Exp. Ther. 321, 308-317
   Abstract »    Full Text »    PDF »
RGS4 Modulates Serotonin Signaling in Prefrontal Cortex and Links to Serotonin Dysfunction in a Rat Model of Schizophrenia.
Z. Gu, Q. Jiang, and Z. Yan (2007)
Mol. Pharmacol. 71, 1030-1039
   Abstract »    Full Text »    PDF »
Habituation Deficits Induced by Metabotropic Glutamate Receptors 2/3 Receptor Blockade in Mice: Reversal by Antipsychotic Drugs.
A. Bespalov, A.-L. Jongen-Relo, M. van Gaalen, S. Harich, H. Schoemaker, and G. Gross (2007)
J. Pharmacol. Exp. Ther. 320, 944-950
   Abstract »    Full Text »    PDF »
Group III Metabotropic Glutamate Receptor Agonists Selectively Suppress Excitatory Synaptic Currents in the Rat Prefrontal Cortex Induced by 5-Hydroxytryptamine2A Receptor Activation.
C. Zhang and G. J. Marek (2007)
J. Pharmacol. Exp. Ther. 320, 437-447
   Abstract »    Full Text »    PDF »
IN VITRO AND IN VIVO EVALUATION OF THE METABOLISM AND BIOAVAILABILITY OF ESTER PRODRUGS OF MGS0039 (3-(3,4-DICHLOROBENZYLOXY)-2-AMINO-6-FLUOROBICYCLO[3.1.0]HEXANE-2,6-DICARBOXYLIC ACID), A POTENT METABOTROPIC GLUTAMATE RECEPTOR ANTAGONIST.
M. Nakamura, Y. Kawakita, A. Yasuhara, Y. Fukasawa, K. Yoshida, K. Sakagami, and A. Nakazato (2006)
Drug Metab. Dispos. 34, 369-374
   Abstract »    Full Text »    PDF »
Improved Bioavailability of the mGlu2/3 Receptor Agonist LY354740 Using a Prodrug Strategy: In Vivo Pharmacology of LY544344.
L. M. Rorick-Kehn, E. J. Perkins, K. M. Knitowski, J. C. Hart, B. G. Johnson, D. D. Schoepp, and D. L. McKinzie (2006)
J. Pharmacol. Exp. Ther. 316, 905-913
   Abstract »    Full Text »    PDF »
A Selective Allosteric Potentiator of Metabotropic Glutamate (mGlu) 2 Receptors Has Effects Similar to an Orthosteric mGlu2/3 Receptor Agonist in Mouse Models Predictive of Antipsychotic Activity.
R. Galici, N. G. Echemendia, A. L. Rodriguez, and P. J. Conn (2005)
J. Pharmacol. Exp. Ther. 315, 1181-1187
   Abstract »    Full Text »    PDF »
Expression of Mutant NMDA Receptors in Dopamine D1 Receptor-Containing Cells Prevents Cocaine Sensitization and Decreases Cocaine Preference.
C. L. Heusner and R. D. Palmiter (2005)
J. Neurosci. 25, 6651-6657
   Abstract »    Full Text »    PDF »
Cinnarizine has an atypical antipsychotic profile in animal models of psychosis.
O. P. Dall'igna, A. B.L. Tort, D. O. Souza, and D. R. Lara (2005)
J Psychopharmacol 19, 342-346
   Abstract »    PDF »
Activation of Medial Prefrontal Cortex by Phencyclidine is Mediated via a Hippocampo-prefrontal Pathway.
E. Jodo, Y. Suzuki, T. Katayama, K.-Y. Hoshino, S. Takeuchi, S.-I. Niwa, and Y. Kayama (2005)
Cereb Cortex 15, 663-669
   Abstract »    Full Text »    PDF »
Differential Modulation of Glutamatergic Transmission by 3,5-Dibromo-L-phenylalanine.
V. Yarotskyy, A. V. Glushakov, C. Sumners, N. Gravenstein, D. M. Dennis, C. N. Seubert, and A. E. Martynyuk (2005)
Mol. Pharmacol. 67, 1648-1654
   Abstract »    Full Text »    PDF »
Activation of Metabotropic Glutamate 2/3 Receptors Reverses the Effects of NMDA Receptor Hypofunction on Prefrontal Cortex Unit Activity in Awake Rats.
H. Homayoun, M. E. Jackson, and B. Moghaddam (2005)
J Neurophysiol 93, 1989-2001
   Abstract »    Full Text »    PDF »
Enhanced cocaine responsiveness and impaired motor coordination in metabotropic glutamate receptor subtype 2 knockout mice.
Y. Morishima, T. Miyakawa, T. Furuyashiki, Y. Tanaka, H. Mizuma, and S. Nakanishi (2005)
PNAS 102, 4170-4175
   Abstract »    Full Text »    PDF »
Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia.
M. F. Egan, R. E. Straub, T. E. Goldberg, I. Yakub, J. H. Callicott, A. R. Hariri, V. S. Mattay, A. Bertolino, T. M. Hyde, C. Shannon-Weickert, et al. (2004)
PNAS 101, 12604-12609
   Abstract »    Full Text »    PDF »
NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex.
M. E. Jackson, H. Homayoun, and B. Moghaddam (2004)
PNAS 101, 8467-8472
   Abstract »    Full Text »    PDF »
Group II metabotropic glutamate receptors enhance NMDA receptor currents via a protein kinase C-dependent mechanism in pyramidal neurones of rat prefrontal cortex.
J. P. Tyszkiewicz, Z. Gu, X. Wang, X. Cai, and Z. Yan (2004)
J. Physiol. 554, 765-777
   Abstract »    Full Text »    PDF »
Evaluation of common gene expression patterns in the rat nervous system.
S. Kaiser and L. K. Nisenbaum (2003)
Physiol Genomics 16, 1-7
   Abstract »    Full Text »    PDF »
White Matter Changes in Schizophrenia: Evidence for Myelin-Related Dysfunction.
K. L. Davis, D. G. Stewart, J. I. Friedman, M. Buchsbaum, P. D. Harvey, P. R. Hof, J. Buxbaum, and V. Haroutunian (2003)
Arch Gen Psychiatry 60, 443-456
   Abstract »    Full Text »    PDF »
Dendritic Glutamate-Induced Bursting in the Prefrontal Cortex: Further Characterization and Effects of Phencyclidine.
W.-X. Shi and X.-X. Zhang (2003)
J. Pharmacol. Exp. Ther. 305, 680-687
   Abstract »    Full Text »    PDF »
The Group II Metabotropic Glutamate Receptor Agonist (-)-2-Oxa-4-aminobicyclo[3.1.0.]hexane-4,6-dicarboxylate (LY379268) and Clozapine Reverse Phencyclidine-Induced Behaviors in Monoamine-Depleted Rats.
C. J. Swanson and D. D. Schoepp (2002)
J. Pharmacol. Exp. Ther. 303, 919-927
   Abstract »    Full Text »    PDF »
The Origin and Neuronal Function of In Vivo Nonsynaptic Glutamate.
D. A. Baker, Z.-X. Xi, H. Shen, C. J. Swanson, and P. W. Kalivas (2002)
J. Neurosci. 22, 9134-9141
   Abstract »    Full Text »    PDF »
Effects of NMDA Receptor Antagonists: Implications for the Pathophysiology of Schizophrenia.
J. H. Krystal, A. Anand, and B. Moghaddam (2002)
Arch Gen Psychiatry 59, 663-664
   Full Text »    PDF »
Glutamate and psychiatric disorders.
E. M. Tsapakis and M. J. Travis (2002)
Adv. Psychiatr. Treat. 8, 189-197
   Full Text »    PDF »
Group II Metabotropic Glutamate Receptors Modulate Extracellular Glutamate in the Nucleus Accumbens.
Z.-X. Xi, D. A. Baker, H. Shen, D. S. Carson, and P. W. Kalivas (2002)
J. Pharmacol. Exp. Ther. 300, 162-171
   Abstract »    Full Text »    PDF »
The Future of Imaging in Drug Discovery.
M. E. Schmidt (2001)
Journal of Pharmacy Practice 14, 427-434
   Abstract »    PDF »
Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic caseseries outcome study.
S. M. Dursun and J. F. W. Deakin (2001)
J Psychopharmacol 15, 297-301
   Abstract »    PDF »
Hyperfunction of Dopaminergic and Serotonergic Neuronal Systems in Mice Lacking the NMDA Receptor {epsilon}1 Subunit.
Y. Miyamoto, K. Yamada, Y. Noda, H. Mori, M. Mishina, and T. Nabeshima (2001)
J. Neurosci. 21, 750-757
   Abstract »    Full Text »    PDF »
DOI-Induced Activation of the Cortex: Dependence on 5-HT2A Heteroceptors on Thalamocortical Glutamatergic Neurons.
J. L. Scruggs, S. Patel, M. Bubser, and A. Y. Deutch (2000)
J. Neurosci. 20, 8846-8852
   Abstract »    Full Text »    PDF »
Ketamine-Induced Deficits in Auditory and Visual Context-Dependent Processing in Healthy Volunteers: Implications for Models of Cognitive Deficits in Schizophrenia.
D. Umbricht, L. Schmid, R. Koller, F. X. Vollenweider, D. Hell, and D. C. Javitt (2000)
Arch Gen Psychiatry 57, 1139-1147
   Abstract »    Full Text »    PDF »
Phencyclidine Model of Frontal Cortical Dysfunction in Nonhuman Primates.
J. D. Jentsch, J. R. Taylor, and R. H. Roth (2000)
Neuroscientist 6, 263-270
   Abstract »    PDF »
Glutamate as a Neurotransmitter in the Brain: Review of Physiology and Pathology.
B. S. Meldrum (2000)
J. Nutr. 130, 1007
   Abstract »    Full Text »
Attenuation of the Neuropsychiatric Effects of Ketamine With Lamotrigine: Support for Hyperglutamatergic Effects of N-methyl-D-aspartate Receptor Antagonists.
A. Anand, D. S. Charney, D. A. Oren, R. M. Berman, X. S. Hu, A. Cappiello, and J. H. Krystal (2000)
Arch Gen Psychiatry 57, 270-276
   Abstract »    Full Text »    PDF »
Physiological Antagonism between 5-Hydroxytryptamine2A and Group II Metabotropic Glutamate Receptors in Prefrontal Cortex.
G. J. Marek, R. A. Wright, D. D. Schoepp, J. A. Monn, and G. K. Aghajanian (2000)
J. Pharmacol. Exp. Ther. 292, 76-87
   Abstract »    Full Text »
Regulation of Locomotor Activity by Metabotropic Glutamate Receptors in the Nucleus Accumbens and Ventral Tegmental Area.
C. J. Swanson and P. W. Kalivas (2000)
J. Pharmacol. Exp. Ther. 292, 406-414
   Abstract »    Full Text »
Substance Abuse, Neurobiology, and Ideology.
J. C. M. Brust (1999)
Arch Neurol 56, 1528-1531
   Full Text »    PDF »
Dopamine Receptors and Groups I and II mGluRs Cooperate for Long-Term Depression Induction in Rat Prefrontal Cortex through Converging Postsynaptic Activation of MAP Kinases.
S. Otani, N. Auclair, J.-M. Desce, M.-P. Roisin, and F. Crepel (1999)
J. Neurosci. 19, 9788-9802
   Abstract »    Full Text »    PDF »
The Metabotropic Glutamate 2/3 Receptor Agonists LY354740 and LY379268 Selectively Attenuate Phencyclidine versus d-Amphetamine Motor Behaviors in Rats.
J. Cartmell, J. A. Monn, and D. D. Schoepp (1999)
J. Pharmacol. Exp. Ther. 291, 161-170
   Abstract »    Full Text »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)